Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/22453
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGarcía Carrasco, Mariocat
dc.contributor.authorPizcueta Lalanza, María Pilarcat
dc.contributor.authorCervera i Segura, Ricard, 1960-cat
dc.contributor.authorRamos Casals, Manuelcat
dc.contributor.authorSisó Almirall, Antonicat
dc.contributor.authorRed, Gloria de lacat
dc.contributor.authorIngelmo Morín, Miguelcat
dc.contributor.authorFont Franco, Josep, 1953-2006cat
dc.contributor.authorEngel Rocamora, Pablocat
dc.date.accessioned2012-03-05T12:52:11Z-
dc.date.available2012-03-05T12:52:11Z-
dc.date.issued2000-
dc.identifier.issn0003-4967ca
dc.identifier.urihttp://hdl.handle.net/2445/22453-
dc.description.abstractOBJECTIVE—Serum concentrations of soluble (s) L-selectin (CD62L) were measured in patients with primary Sjögren's syndrome (SS) to relate these concentrations to clinical and immunological features of SS.
METHODS—The study included 40 consecutive patients (38 women and two men) with a mean age of 61 years (range 24-78) who fulfilled four or more of the preliminary diagnostic criteria for SS proposed by the European Community Study Group in 1993, and 33 healthy blood donors from the hospital blood bank. A sandwich enzyme linked immunosorbent assay (ELISA) was used to detect the soluble form of human sL-selectin (CD62L).
RESULTS—The mean (SEM) values of sL-selectin (CD62L) were 861 (66) µg/ml for patients with SS and 986 (180) µg/ml for healthy blood donors, but there was no significant difference. In patients with primary SS, serum sL-selectin (CD62L) concentrations were significantly higher in patients with Raynaud's phenomenon (1275 (112) µg/ml versus 789 (69) µg/ml, p=0.007), autoimmune thyroiditis (1162 (113) µg/ml versus 787 (69) µg/ml, p=0.02) and rheumatoid factor (993 (95) µg/ml versus 684 (70) µg/ml, p=0.01) when compared with patients without these features.
CONCLUSION—The presence of Raynaud's phenomenon, autoimmune thyroiditis and rheumatoid factor is associated with higher concentrations of circulating sL-selectin (CD62L) in the sera of patients with primary SS.

-
dc.format.extent3 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoengeng
dc.publisherBMJ Group-
dc.relation.isformatofReproducció digital del document publicat a: http://dx.doi.org/10.1136/ard.59.4.297-
dc.relation.ispartofAnnals of the Rheumatic Diseases, 2000, vol. 59, núm 4, p. 297-299-
dc.relation.urihttp://dx.doi.org/10.1136/ard.59.4.297-
dc.rights(c) BMJ Publishing Group Ltd, 2000-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationProteïnescat
dc.subject.classificationReceptors cel·lularscat
dc.subject.classificationSíndrome de Sjögrencat
dc.subject.classificationLeucòcitscat
dc.subject.otherProteinseng
dc.subject.otherCell receptorseng
dc.subject.otherSjogren's syndromeeng
dc.subject.otherLeucocyteseng
dc.titleCirculating concentrations of soluble L-selectin (CD62L) in patients with primary Sjögren's syndrome.eng
dc.typeinfo:eu-repo/semantics/articleca
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec568766ca
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid10733478-
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
568766.pdf124.49 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.